We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.15% | 148.95 | 149.73 | 148.70 | 149.12 | 7,121,280 | 21:33:38 |
From May 2019 to May 2024
By Lisa Beilfuss
Johnson & Johnson said Wednesday that its Janssen Pharmaceutical segment plans to file for regulatory approval of at least 10 new drugs by 2019, each with the potential to exceed $1 billion in revenue.
The company also said it plans more than 40 line extensions of existing and new medicines.
"We look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines," said Joaquin Duato, world-wide pharmaceuticals chairman. "We are working with our partners to advance the innovative products in our pipeline and to deliver significant benefits to patients."
J&J said late-stage products expected to drive growth in the next several years include daratumumab for multiple myeloma, sirukumab for rheumatoid arthritis, and guselkumab for psoriasis.
The company meets with industry analysts Wednesday.
Shares, down 0.6% this year, rose 0.5% to $104.50 in premarket trading.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
Access Investor Kit for Johnson & Johnson
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US4781601046
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
